CLS CLS Special Populations in Lipid Management 2 — Questions and Answers
Question 1: In patients with type 1 diabetes, what lipid abnormality is most commonly seen when diabetes is well-controlled?
- Near-normal lipid profiles, as insulin facilitates lipid metabolism (Correct answer)
- Severe LDL elevation
- Markedly elevated triglycerides
- Isolated low HDL
Correct answer: Near-normal lipid profiles, as insulin facilitates lipid metabolism
Well-controlled type 1 diabetes is associated with near-normal or even above-normal HDL-C and relatively normal lipid profiles due to adequate insulin levels.
Question 2: A post-menopausal woman is considering hormone replacement therapy (HRT). Which lipid effect distinguishes oral from transdermal estrogen preparations?
- Oral estrogen increases triglycerides; transdermal estrogen has minimal triglyceride effect (Correct answer)
- Transdermal estrogen raises LDL more than oral
- Oral estrogen lowers HDL-C
- Both formulations have identical lipid effects
Correct answer: Oral estrogen increases triglycerides; transdermal estrogen has minimal triglyceride effect
Oral estrogen undergoes first-pass hepatic metabolism, stimulating VLDL and triglyceride production, whereas transdermal estrogen bypasses the liver and has minimal triglyceride impact.
Question 3: In patients with metabolic syndrome, which lipid triad is characteristically found?
- Elevated triglycerides, low HDL-C, and increased small dense LDL particles (Correct answer)
- Markedly elevated LDL-C, normal triglycerides, and high HDL-C
- Isolated elevated Lp(a) with normal other lipids
- Very high total cholesterol with normal LDL-C
Correct answer: Elevated triglycerides, low HDL-C, and increased small dense LDL particles
Metabolic syndrome classically presents with the atherogenic dyslipidemia triad: hypertriglyceridemia, low HDL-C, and predominance of small dense LDL particles.
Question 4: Which statin dose adjustment is recommended in patients with severe hepatic impairment (Child-Pugh Class C)?
- Statins are contraindicated in active liver disease and severe hepatic impairment (Correct answer)
- Reduce statin dose by 50% and monitor LFTs monthly
- Use water-soluble statins only at normal doses
- No adjustment needed if LFTs are less than 5× ULN
Correct answer: Statins are contraindicated in active liver disease and severe hepatic impairment
Statins are contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases, including severe hepatic impairment.
Question 5: In patients undergoing solid organ transplantation on cyclosporine, which statin interaction is most clinically significant?
- Cyclosporine markedly increases statin levels by inhibiting CYP3A4 and OATP1B1, increasing myopathy risk (Correct answer)
- Cyclosporine lowers statin levels, requiring dose increases
- Only fibrates interact with cyclosporine
- The interaction only affects pravastatin
Correct answer: Cyclosporine markedly increases statin levels by inhibiting CYP3A4 and OATP1B1, increasing myopathy risk
Cyclosporine inhibits both CYP3A4 and OATP1B1 transporters, dramatically increasing systemic statin exposure and myopathy/rhabdomyolysis risk.
Question 6: In patients with hypothyroidism, what is the recommended approach to managing hyperlipidemia?
- Treat hypothyroidism first with thyroid hormone replacement before reassessing lipid levels (Correct answer)
- Start statin therapy immediately regardless of TSH status
- Use fibrates as first-line therapy
- Perform lipid testing only after 6 months of observation
Correct answer: Treat hypothyroidism first with thyroid hormone replacement before reassessing lipid levels
Hypothyroidism is a reversible cause of dyslipidemia; correcting thyroid hormone deficiency often normalizes lipid levels, avoiding unnecessary statin therapy.
CLS CLS Special Populations in Lipid Management 2
In patients with type 1 diabetes, what lipid abnormality is most commonly seen when diabetes is well-controlled?